| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Hung-Yu Chan, An-Sheng Lin, Kun-Po Chen, Jror-Serk Cheng, Ying-Yeh Chen, Chang-Jer Tsa. An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation. Journal of clinical psychopharmacology. vol 33. issue 6. 2014-09-15. PMID:24100785. |
thirty-nine patients with schizophrenia (diagnostic and statistical manual of mental disorders, fourth edition) who met the criteria of a positive and negative syndrome scale (panss) total score of greater than or equal to 60 points, panss-excitement component (ec) score of greater than or equal to 14 points, and at least 1 panss-ec score of greater than or equal to 4 were randomly assigned to either the zotepine or risperidone group. |
2014-09-15 |
2023-08-12 |
Not clear |
| Sebastian Walther, Franz Moggi, Helge Horn, Konstantin Moskvitin, Christoph Abderhalden, Nadja Maier, Werner Strik, Thomas J Mülle. Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine. Journal of clinical psychopharmacology. vol 34. issue 1. 2014-08-29. PMID:24346752. |
we aimed to investigate the efficacy of oral haloperidol, risperidone, and olanzapine in reducing psychotic agitation in severely agitated patients with schizophrenia or schizophreniform or schizoaffective disorder over 96 hours using a prospective, randomized, rater-blinded, controlled design within a naturalistic treatment regimen. |
2014-08-29 |
2023-08-12 |
Not clear |
| b' Zofia Rog\\xc3\\xb3\\xc5\\xb. Effect of combined treatment with mirtazapine and risperidone on the MK-801-induced changes in the object recognition test in mice. Pharmacological reports : PR. vol 65. issue 5. 2014-08-25. PMID:24399737.' |
several clinical reports have suggested that the mirtazapine-induced augmentation of risperidone activity may effectively improve treatment of the negative and certain cognitive symptoms of schizophrenia. |
2014-08-25 |
2023-08-12 |
mouse |
| Judith Usall, Raquel López-Carrilero, Raquel Iniesta, Mercedes Roca, Montserrat Caballero, Roberto Rodriguez-Jimenez, Cristina Oliveira, Miguel Bernardo, Iluminada Corripio, Santiago Durán Sindreu, Jose Carlos González Piqueras, Ana Espliego Felipe, Blanca Fernandez de Corres, Angela Ibáñez, Raúl Huert. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia. The Journal of clinical psychiatry. vol 75. issue 6. 2014-08-25. PMID:25004184. |
in this study, we assessed the efficacy of 2 pharmacodynamically different antidepressants, citalopram (a selective serotonin reuptake inhibitor) and reboxetine (a norepinephrine reuptake inhibitor), as adjunctive therapy to risperidone and olanzapine for the treatment of negative symptoms in schizophrenia. |
2014-08-25 |
2023-08-13 |
Not clear |
| W P Clarke, T A Chavera, M Silva, L C Sullivan, K A Ber. Signalling profile differences: paliperidone versus risperidone. British journal of pharmacology. vol 170. issue 3. 2014-08-19. PMID:23826915. |
paliperidone is an active metabolite of the second-generation atypical antipsychotic, risperidone recently approved for the treatment of schizophrenia and schizoaffective disorder. |
2014-08-19 |
2023-08-12 |
Not clear |
| Jianjun Liu, Jushui Sun, Xinghua Shen, Weigang Guo, Shengli Zhi, Guangming Song, Qiuxia Xu, Juanfen Son. Randomized controlled trial comparing changes in serum prolactin and weight among female patients with first-episode schizophrenia over 12 months of treatment with risperidone or quetiapine. Shanghai archives of psychiatry. vol 26. issue 2. 2014-08-05. PMID:25092954. |
randomized controlled trial comparing changes in serum prolactin and weight among female patients with first-episode schizophrenia over 12 months of treatment with risperidone or quetiapine. |
2014-08-05 |
2023-08-13 |
Not clear |
| Dong-Jing Fu, Cynthia A Bossie, Jennifer K Sliwa, Yi-Wen Ma, Larry Alph. Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison. International clinical psychopharmacology. vol 29. issue 1. 2014-07-17. PMID:24113628. |
paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison. |
2014-07-17 |
2023-08-12 |
Not clear |
| Mehdi Farokhnia, Anita Azarkolah, Forod Adinehfar, Mohammad-Reza Khodaie-Ardakani, Seyed-Mohammad-Reza Hosseini, Habibeh Yekehtaz, Mina Tabrizi, Farzin Rezaei, Bahman Salehi, Seyed-Mohammad-Hossein Sadeghi, Marzieh Moghadam, Fardin Gharibi, Omid Mirshafiee, Shahin Akhondzade. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. Clinical neuropharmacology. vol 36. issue 6. 2014-07-08. PMID:24201233. |
n-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. |
2014-07-08 |
2023-08-12 |
Not clear |
| Mehdi Farokhnia, Anita Azarkolah, Forod Adinehfar, Mohammad-Reza Khodaie-Ardakani, Seyed-Mohammad-Reza Hosseini, Habibeh Yekehtaz, Mina Tabrizi, Farzin Rezaei, Bahman Salehi, Seyed-Mohammad-Hossein Sadeghi, Marzieh Moghadam, Fardin Gharibi, Omid Mirshafiee, Shahin Akhondzade. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. Clinical neuropharmacology. vol 36. issue 6. 2014-07-08. PMID:24201233. |
this study aimed to evaluate the possible effects of nac as an adjunct to risperidone in treating negative symptoms of schizophrenia. |
2014-07-08 |
2023-08-12 |
Not clear |
| Evangelia Eirini Tsermpini, Konstantinos Assimakopoulos, Marina Bartsakoulia, Gregoris Iconomou, Eleni Merkouri Papadima, Konstantinos Mitropoulos, Alessio Squassina, George P Patrino. Individualizing clozapine and risperidone treatment for schizophrenia patients. Pharmacogenomics. vol 15. issue 1. 2014-07-07. PMID:24329194. |
individualizing clozapine and risperidone treatment for schizophrenia patients. |
2014-07-07 |
2023-08-12 |
Not clear |
| Haizhi Chen, Mincai Qian, Xinhua Shen, Shengliang Yang, Jianhong Yang, Juanfang Song, Xiaocong Fei, Baiping Tao, Baohua Song, Lihua Ren, Zhongxia She. Risk factors for medication-induced amenorrhea in first-episode female Chinese patients with schizophrenia treated with risperidone. Shanghai archives of psychiatry. vol 25. issue 1. 2014-07-03. PMID:24991131. |
risk factors for medication-induced amenorrhea in first-episode female chinese patients with schizophrenia treated with risperidone. |
2014-07-03 |
2023-08-13 |
Not clear |
| Aerrolla Navitha, Satheesh Jogala, Chinnala Krishnamohan, Jithan Aukunur. Development of novel risperidone implants using blends of polycaprolactones and in vitro in vivo correlation studies. Journal of advanced pharmaceutical technology & research. vol 5. issue 2. 2014-06-24. PMID:24959417. |
the objective of this study was to develop a novel implant containing risperidone intended for long-term treatment in schizophrenia utilizing in vitro in vivo correlation (ivivc) studies. |
2014-06-24 |
2023-08-13 |
rat |
| S K Sha. A comparative study of sexual dysfunction in schizophrenia patients taking aripiprazole versus risperidone. Kathmandu University medical journal (KUMJ). vol 11. issue 42. 2014-06-23. PMID:24096218. |
a comparative study of sexual dysfunction in schizophrenia patients taking aripiprazole versus risperidone. |
2014-06-23 |
2023-08-12 |
Not clear |
| D Lecompte, R F Cookso. The economic value of atypical antipsychotics: A comparison of risperidone and olanzapine revisited. International journal of psychiatry in clinical practice. vol 3. issue 1. 2014-06-21. PMID:24945060. |
since launch, the optimal dose for treatment of schizophrenia of risperidone has been established at 4-6 mg/day and that of olanzapine at around 15 mg/day. |
2014-06-21 |
2023-08-13 |
Not clear |
| D Lecompte, R F Cookso. The economic value of atypical antipsychotics: A comparison of risperidone and olanzapine revisited. International journal of psychiatry in clinical practice. vol 3. issue 1. 2014-06-21. PMID:24945060. |
we have applied these more realistic dosing assumptions to the published economic comparisons between the various atypical agents and conclude that there are economic and efficacy arguments for risperidone to be considered as the first choice for treatment of patients with schizophrenia. |
2014-06-21 |
2023-08-13 |
Not clear |
| Mia A C Mudge, Peter J Davey, Dr Kristina A Coleman, William Montgomery, Victoria S Croker, Karen Mullen, David J Castl. A comparison of olanzapine versus risperidone for the treatment of schizophrenia: a meta-analysis of randomised clinical trials. International journal of psychiatry in clinical practice. vol 9. issue 1. 2014-06-21. PMID:24945331. |
a comparison of olanzapine versus risperidone for the treatment of schizophrenia: a meta-analysis of randomised clinical trials. |
2014-06-21 |
2023-08-13 |
Not clear |
| Mia A C Mudge, Peter J Davey, Dr Kristina A Coleman, William Montgomery, Victoria S Croker, Karen Mullen, David J Castl. A comparison of olanzapine versus risperidone for the treatment of schizophrenia: a meta-analysis of randomised clinical trials. International journal of psychiatry in clinical practice. vol 9. issue 1. 2014-06-21. PMID:24945331. |
objective this meta-analysis was carried out to compare the efficacy and safety of olanzapine with risperidone in the treatment of schizophrenia. |
2014-06-21 |
2023-08-13 |
Not clear |
| Massimo Carlo Mauri, Martin Turner, Lucia S Volonteri, Rossella Medori, Wolfgang Maie. Dosing patterns in Europe: Efficacy and safety of risperidone long-acting injectable in doses of 25, 37.5 and 50 mg. International journal of psychiatry in clinical practice. vol 13. issue 1. 2014-06-21. PMID:24946121. |
to assess the dose prescription patterns for risperidone long-acting injectable (rlai) in patients with schizophrenia who participated in the 6-month, open-label switch to risperidone microspheres (stormi) trial. |
2014-06-21 |
2023-08-13 |
Not clear |
| Virginia L Stauffer, Brian A Millen, Scott Andersen, Bruce J Kinon, Lisa Lagrandeur, J P Lindenmayer, Juan Carlos Gome. Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophrenia research. vol 150. issue 2-3. 2014-06-20. PMID:24035403. |
this parallel-group, 16-week study enrolled adults with schizophrenia who were receiving standard of care (soc) therapy, which included ≥3months treatment with one of four sgas: aripiprazole, olanzapine, risperidone, or quetiapine. |
2014-06-20 |
2023-08-12 |
Not clear |
| Steven G Potkin, Phillip Phiri, Armin Szegedi, Jun Zhao, Larry Alphs, Pilar Cazorl. Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis. Schizophrenia research. vol 150. issue 2-3. 2014-06-20. PMID:24075603. |
a phase 2 efficacy study suggested that asenapine (ase) was superior to risperidone in decreasing negative symptoms in schizophrenia at 6 weeks, prompting design of two negative symptom studies. |
2014-06-20 |
2023-08-12 |
Not clear |